ArticlePloS one2025
Do skin bacteriostatic agents reduce acute radiodermatitis in breast cancer patients? A prospective interventional study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRadiodermatitis is the most prevalent complication in breast cancer patients undergoing radiotherapy. Emerging evidence suggests a correlation between radiodermatitis and Staphylococcus aureus colonization. The aim of our study was to explore whether the application of skin bacteriostatic agents (a sterile liquid dressing containing fucoidan oligosaccharides with anti-Staphylococcus aureus activity) could mitigate acute radiodermatitis in breast cancer patients.
methodsWe conducted a prospective interventional study, enrolling breast cancer patients receiving outpatient radiotherapy at our institution from July 1, 2023, to January 31, 2024. Patients were divided into an experimental group and a control group based on the usage of skin bacteriostatic agents. The first outcome was evaluated using the Radiation Therapy Oncology Group (RTOG) criteria. The second outcome was the patient's reported symptoms of radiodermatitis, which included itching, pain, tightness, burning and swelling. The third outcome was whether the usage of skin bacteriostatic agents delayed the onset of self-reported radiodermatitis symptoms.
resultsA total of 183 patients were enrolled, comprising 101 breast-conserving patients (21 in the experimental group, 80 in the control group); and 82 mastectomy patients (26 in the experimental group, 56 in the control group). The experimental group showed a significantly lower grade of radiodermatitis compared to the control group in both breast-conserving and mastectomy patients (P < 0.05). Patient-reported symptoms of radiodermatitis included itching (54.6%), pain (48.1%), tightness (21.9%), burning (11.5%), and swelling (17.5%), but there was no difference between the two groups and onset in radiodermatitis. Further analysis indicated that hypofractionated radiotherapy could reduce the severity of radiodermatitis and itchiness.
conclusionSkin bacteriostatic agents used during radiotherapy can reduce the severity of radiodermatitis in breast cancer patients, although it does not alleviate self-reported symptoms of dermatitis. Hypofractionated radiotherapy is recommended to reduce the severity of radiodermatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.